Abstract
Stroke and cancer have significant morbidity and mortality with heterogeneous risk factors. While conventional risk factors such as atherosclerosis and cardiac disease are important mechanisms in the occurrence of stroke, cancer is an unconventional risk factor that leads to both ischemic and hemorrhagic stroke in a myriad of ways. Although cancer-associated strokes have unique underlying mechanisms, the clinical features, diagnosis, and management scheme are similar for non-cancer-associated strokes. Prognosis is complex and is dependent on the stage and type of cancer, expected treatment course, and stroke burden.
References
Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18. https://doi.org/10.1056/nejmoa1713973.
Amer M. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res. 2013; 5: 165. https://doi.org/10.2147/cmar.s47094.
Atterman A, Gigante B, Asplund K, et al. Cancer diagnosis as a risk factor of ischemic stroke in atrial fibrillation patients with low stroke risk score. Thromb Res. 2018;164:S209. https://doi.org/10.1016/j.thromres.2018.02.064.
Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158–64. https://doi.org/10.3324/haematol.2011.054718.
Bang OY, Seok JM, Kim SG, et al. Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol. 2011;7:53. https://doi.org/10.3988/jcn.2011.7.2.53.
Bartynski W. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol. 2008;29:1043–9. https://doi.org/10.3174/ajnr.a0929.
Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349:109–11. https://doi.org/10.1056/nejmp030086.
Blom JW. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715. https://doi.org/10.1001/jama.293.6.715.
Bradley WG. MR appearance of hemorrhage in the brain. Radiology. 1993;189:15–26. https://doi.org/10.1148/radiology.189.1.8372185.
Cheng SW, Wu LL, Ting AC, et al. Irradiation-induced extracranial carotid stenosis in patients with head and neck malignancies. Am J Surg. 1999;178:323–8. https://doi.org/10.1016/s0002-9610(99)00184-1.
Cocho D, Gendre J, Boltes A, et al. Predictors of occult cancer in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2015;24:1324–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.02.006.
Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke. 2015;47:581–641. https://doi.org/10.1161/str.0000000000000086.
Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol. 2001; 106: 18–24. https://doi.org/10.1159/000046585.
Gemmete JJ, Pandey AS, Chaudhary N, et al. Paradoxical embolus to the brain from embolization of a carotid body tumor. J Neurointerv Surg. 2011;4:e12.
Gonzalez-Quintela A, Candela M, Vidal C, et al. Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol. 1991;46:1–9.
Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine. 1985; 64:16–35. https://doi.org/10.1097/00005792-198501000-00002.
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29. https://doi.org/10.1056/nejmoa0804656.
Haynes JC, Machtay M, Weber RS, et al. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation. Laryngoscope. 2002;112:1883–7. https://doi.org/10.1097/00005537-200210000-00034.
Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46:2032–60. https://doi.org/10.1161/str.0000000000000069.
Jang H, Lee JJ, Lee MJ, et al. Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke. J Oncol. 2015;2015:1–6. https://doi.org/10.1155/2015/502089.
Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947. https://doi.org/10.1161/str.0b013e318284056a.
Kabre R, Kamble K. Gemcitabine and Cisplatin induced posterior reversible encephalopathy syndrome: a case report with review of literature. J Res Pharm Pract. 2016;5:297. https://doi.org/10.4103/2279-042x.192464.
Kase CS. Intracerebral hemorrhage: non-hypertensive causes. Stroke. 1986;17:590–5. https://doi.org/10.1161/01.str.17.4.590.
Kim K, Lee J-H. Risk factors and biomarkers of ischemic stroke in cancer patients. J Stroke. 2014;16:91. https://doi.org/10.5853/jos.2014.16.2.91.
Kim J-M, Jung K-H, Park KH, et al. Clinical manifestation of cancer related stroke: retrospective case–control study. J Neurooncol. 2013;111:295–301. https://doi.org/10.1007/s11060-012-1011-4.
Mohr JP. Stroke: pathophysiology, diagnosis, and management. Philadelphia: Elsevier/Saunders; 2011.
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2016 update. Circulation. 2015;133:e38. https://doi.org/10.1161/cir.0000000000000350.
Murata J-I, Sawamura Y, Takahashi A, et al. Intracerebral hemorrhage caused by a neoplastic aneurysm from small-cell lung carcinoma. Neurosurgery. 1993;32:124–6. https://doi.org/10.1227/00006123-199301000-00019.
Navi BB, Singer S, Merkler AE, et al. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology. 2014a;83:26–33. https://doi.org/10.1212/wnl.0000000000000539.
Navi BB, Singer S, Merkler AE, et al. Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke. Stroke. 2014b;45: 2292–7. https://doi.org/10.1161/strokeaha.114.005784.
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–38. https://doi.org/10.1016/j.jacc.2017.06.047.
Navi BB, Marshall RS, Bobrow D, et al. Enoxaparin vs aspirin in patients with cancer and ischemic stroke. JAMA Neurol. 2018;75:379. https://doi.org/10.1001/jamaneurol.2017.4211.
Nguyen T, DeAngelis LM. Stroke in cancer patients. Curr Neurol Neurosci Rep. 2006;6:187–92. https://doi.org/10.1007/s11910-006-0004-0.
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11–21. https://doi.org/10.1056/nejmoa1706442.
Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830–8. https://doi.org/10.1001/jama.286.22.2830.
Pollack CV, Reilly PA, Ryn JV, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377:431–41. https://doi.org/10.1056/nejmoa1707278.
Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment. Stroke. 2015;46: 3020–35. https://doi.org/10.1161/str.0000000000000074.
Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46. https://doi.org/10.1161/str.0000000000000158.
Quintas S, Rogado J, Gullón P, et al. Predictors of unknown cancer in patients with ischemic stroke. J Neurooncol. 2018;137:551–7. https://doi.org/10.1007/s11060-017-2741-0.
Rha J-H, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967–73. https://doi.org/10.1161/01.str.0000258112.14918.24.
Selvik HA, Thomassen L, Bjerkreim AT, et al. Cancer-associated stroke: the Bergen NORSTROKE study. Cerebrovasc Dis Extra. 2015;5:107–13. https://doi.org/10.1159/000440730.
Shin Y-W, Lee S-T, Jung K-H, et al. Predictors of survival for patients with cancer after cryptogenic stroke. J Neurooncol. 2016;128:277–84. https://doi.org/10.1007/s11060-016-2106-0.
Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2008;63:761–7.
Smets G-J, Loyson T, Paesschen WV, et al. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review. Acta Clin Belg. 2017; 1–7. https://doi.org/10.1080/17843286.2017.1403103.
Sorgun MH, Kuzu M, Ozer IS, et al. Risk factors, biomarkers, etiology, outcome and prognosis of ischemic stroke in cancer patients. Asian Pac J Cancer Prev. 2018;19:649–53.
Stefan O, Vera N, Otto B, et al. Stroke in cancer patients: a risk factor analysis. J Neurooncol. 2009;94: 221–6. https://doi.org/10.1007/s11060-009-9818-3.
Sun B, Fan S, Li Z, et al. Clinical and neuroimaging features of acute ischemic stroke in cancer patients. Eur Neurol. 2016;75:292–9. https://doi.org/10.1159/000447126.
Thaler DE, Saver JL. Cryptogenic stroke and patent foramen ovale. Curr Opin Cardiol. 2008;23:537–44. https://doi.org/10.1097/hco.0b013e32831311bd.
Thomalla G, Cheng B, Ebinger M, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol. 2011;10:978–86. https://doi.org/10.1016/s1474-4422(11)70192-2.
Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364–72. https://doi.org/10.1016/s0140-6736(12)60738-7.
Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.cd000213.pub3.
Wijdicks EFM, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1222–38. https://doi.org/10.1161/01.str.0000441965.15164.d6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Bowry, R., Grotta, J.C. (2019). Stroke in Critically Ill Cancer Patients. In: Nates, J., Price, K. (eds) Oncologic Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-74698-2_35-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-74698-2_35-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74698-2
Online ISBN: 978-3-319-74698-2
eBook Packages: Springer Reference MedicineReference Module Medicine